Alnylam Pharmaceuticals Inc. is banking on its drug Onpattro becoming the foundation stone for a multi-billion dollar franchise in amyloidosis – but the runaway success of Pfizer’s rival Vyndaqel could upset those plans.
Pfizer’s Vyndaqel Success Interfering With Alnylam's Plans
Blockbuster Status In Sight For Pfizer Drug
Alnylam wants to emulate success of Eylea and Revlimid in amyloidosis– but Pfizer could spoil the plan.
